A promising treatment for HER2-positive breast cancer Korean scientists found that HVH-2930, an innovative HSP90 inhibitor, demonstrates promising efficacy in inducing cancer cell apoptosis and overcoming treatment resistance in HER2-positive breast cancer. Unlike previous HSP90 inhibitors, the compound ci...
A HER2-positive status is generally associated with more aggressive disease and a worse prognosis. Furthermore, a positive HER2 status may predict the likelihood of resistance to some conventional therapies, as well as probably being predictive of sensitivity to anthracycline dose intensification. In ...
“We've completely flipped the outcomes for HER2-positive breast cancer, where it has gone from one of the most feared types of breast cancer to one of the most successfully treated types of breast cancer.”—Harold Burstein byPeter Attia ...
Inflammatory breast cancer (IBC) is an uncommon and aggressive presentation of locally advanced breast cancer that is potentially curable when localized but may be associated with distant metastasis in up to one-third of patients at presentation. The diagnosis of IBC is made based on clinical ...
Approximately 20 percent of breast cancers are HER2+, meaning they over-express the HER2 gene, resulting in a particularly aggressive form of the disease.4 The first targeted treatment approved to treat HER2+ breast cancer was Herceptin® (trastuzumab) “” in which the BCRP provided...
Inavolisib (Itovebi, previously GDC-0077) plus palbociclib (Ibrance) and fulvestrant gained FDA approval for the management of hormone receptor-positive (HR+), HER2-negative (HER2–), PIK3CA-mutated breast cancer. This approval is based on data from the phase 3 INAVO120 study (NCT04191499)...
trastuzumab (Herceptin) is an antibody to HER2, a growth factor receptor sometimes overexpressed in breast cancer (Nahta 2003; Vu 2012). Trastuzumab was approved by the FDA in 1998 to treat human epidermal growth factor receptor-2-positive (HER2+) breast cancer. By binding to HER2, trastuzumab...
In addition, some people may find that using enhancement pills improves their confidence and overall well-being, which can also have a positive impact on their sex lives. Alternatives to Enhancement Pills If you are considering using enhancement pills, it is important to talk to your doctor first...
identified only 16 tumors (0.13%) with NTRK gene fusions among 12,214 locally aggressive, relapsed, or metastatic BC using comprehensive genomic profiling. Among them, nine cases were ductal carcinomas and three were secretory carcinomas. All tumors were HER2 negative, more commonly TNBC, and ...
HER2-positive (HER2+) cancer represents 15–20 % of BC subtypes. HER2+ confers more aggressive biological and clinical behaviour [36]. These tumours present a high expression of the HER2 gene and of other genes associated with the HER2 pathway [37]. Currently, the treatment in advanced HER2...